ArticleFrontiers in pharmacology2026
Nitazoxanide alleviates collagen-induced arthritis by inhibiting STAT3-dependent Th17 cell differentiation and inflammatory cytokines production.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nitazoxanide (NTZ), an FDA-approved anti-parasitic drug, has shown anti-inflammatory effects in rheumatoid arthritis (RA) fibroblast-like synoviocytes, yet its impact on immune cell function and its potential synergy with methotrexate (MTX) remains unclear. In this study, using a murine collagen-induced arthritis (CIA) model, we demonstrated that NTZ synergizes with MTX to delay arthritis onset and ameliorate joint pathology, accompanied by reduced inflammatory cell infiltration, synovial pannus formation, and bone destruction. Moreover, NTZ significantly suppressed inflammatory cytokine production in both murine splenocytes and human peripheral blood mononuclear cells from healthy donors and RA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.